Day 2 :
Keynote Forum
Roseane M Santos
South University School of Pharmacy, USA
Keynote: Coffee consumption: A genetic approach
Time : 09:00-09:25
Biography:
Roseane Maria Maia Santos is BS in Pharmacy and Biochemistry, MS in Hospital Pharmacy, both from Federal University of Rio de Janeiro, Brazil. She completed her PhD in Pharmaceutical Sciences at SUNY at Buffalo, New York. Later, she was appointed as Assistant Professor at Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL. At present, she is an Associate Professor at South University School of Pharmacy, Savannah, GA, lecturing on various topics in pharmacology, biochemistry and molecular biology. Her research laboratory is focused on bioactive compounds present in coffee and coffee and health effects.
Abstract:
Coffee is among the most widely consumed beverages in the World. Coffee consumption has been receiving a lot of attentionrnin regards to its potential health benefits and risks as well. Caffeine, polycyclic phenols such as chlorogenic acids are somernof the most studied constituents from coffee. It has been attributed to various properties to those compounds such as central nervous system stimulant and antioxidants respectively. Coffee is in fact a very complex mixture that varies according withrnthe origin of the beans and roasting process. A new approach to look into possible effects of drugs is through genetic andrngenomic studies. Actually, it was recently created The Coffee and Caffeine Genetics Consortium with the purpose to identify DNA loci associated with habitual coffee consumption. The technique utilized is called genome-wide meta-analysis (GWMA). This seminar intends to briefly review the results obtained so far. Following the presentation of this seminar, we will open arnworkshop that will focus in 3 main areas of interest:rn• Pharmacogenomics of coffee consumptionrn• What’s inside a cup of coffee • Epidemiology of coffee consumption
Keynote Forum
Roger W Jelliffe
University of Southern California, USA
Keynote: Managing Drug Dosage in the ICU – is Augmented Renal Clearance what we really want to Know?
Time : 09:25-09:50
Biography:
Roger Jelliffe MD, FCP, FAAPS, developed the first computer software for individualizing drug dosage regimens in 1967. He was the first to relate renal drug elimination to creatinine clearance. He developed the first method for estimating creatinine clearance when serum creatinine is changing. He founded the USC Laboratory of Applied Pharmacokinetics in 1973, and the USC*PACK and more recent MM-USCPACK clinical software for individualizing drug dosage regimens most precisely. His laboratory developed the Resource for Population Modeling at the San Diego Supercomputer Center, the nonparametric adaptive grid (NPAG) population modeling approach, and Multiple Model (MM) design of maximally precise dosage regimens. This is now the Bestdose clinical and Pmetrics research software. We have developed three new methods of Bayesian analysis for individual patients. This adds great capability and safety in managing unusual patients.He is author or co-author of 132 peer reviewed publications, has mentored over 100 visiting scientific scholars, 1 sabbatical scholar, 2 Master’s Students, 3 Ph.D candidates, and 3 mini-sabbaticals.
Abstract:
Clearance (CL) is often felt to be the most physiologic parameter to describe elimination of substances from the body, and to be an independent parameter. However, there is an intimate relationship between CL, apparent volume of distribution (V) and the rate constant for elimination (K), in which CL = V times K, K = CL/V, and V = CL/K. Clearly none is independent. If one looks at general ways of describing similar systems, radioactive decay for example, there is no V, and K is the parameter giving accurate information about disappearance. In general, one can describe the behavior of a system as amount in a compartment, and the rate of movement from one compartment to another in terms of rate constants K. Observations of concentrations can be made as amount/V. CL is never needed. Further, since CL = KV, and since K has units of 1/time and V has units of volume, the units of CL are volume/time, and the actual information of rate of movement of drug becomes obscured when CL is used. However, V and K each give direct information about drug behavior. CL is not needed at all. CL is an unnecessary parameter. Further, since unstable ICU patients often have both rapidly changing renal function and unstable fluid balance at the same time, CL comingles and obscures the information of V and K, while V and K carry the needed information directly. This also facilitates separation of the two clinical issues of fluid balance and drug dosage for optimal management of these separate problems. Further, since ICU patients are so often unstable, conventional software for analyzing data of therapeutic drug monitoring (TDM) is no longer very useful, as it assumes that all the patent’s pharmacokinetic (PK) parameters are fixed and unchanging over the period of the data analysis. However, the interacting multiple model (IMM) algorithm developed in the aerospace community for tracking hostile targets most precisely has been developed [1] and implemented in the Bestdose clinical software [2] specifically to deal with this clinical situation. It tracks gentamicin and vancomycin in post-cardiac surgical ICU patients better than other methods [3]. It tracks changes in V and K as each new data point becomes available, resulting in the most recent Bayesian posterior parameter distributions. These then provide the foundation for dosage regimens to achieve desired target drug concentrations in the near future with maximum precision, using multiple model (MM) dosage design [4]. Illustrative clinical cases will be presented and discussed.
Keynote Forum
Yousef A Alomi
Ministry of Health, Saudi Arabia
Keynote: Hotline calling services of national drug information center in Saudi Arabia
Time : 09:50-10:15
Biography:
Dr. Yousef Alomi, Head of General Administration of Pharmaceutical Care Administration, and Head of National Drug Information Center, MOH Saudi Arabia Dr. Alomi is a product of King Saud University confirmed with the degree of Bachelor of Pharmaceutical Sciences in the year 1992. After six-years of higher study, he earned his Master of Clinical Pharmacy from the same university in the 1998. He is an affiliated clinical instructor of Purdue University in the USA. He is adjunct assistant professor of King Saud University college of Pharmacy. Dr. Alomi was a member of Pharmacy Board at Saudi commission for health Specialties for 1998-2002 and 2008-2012 and Head of Pharmacy Accreditation committee in 2010-2012. He was team member of establishing 1st Pharmacy Residency Program in Saudi Arabia . In the year 2005 he obtained Board Certification of Pharmacotherapy Specialist (BCPS). In the year 2008, he obtained his diploma in business administration from American University in Egypt in 2007, and he obtained a Board Certification of Nutrition Support Pharmacy (BCNSP) in 2009. Dr. Alomi worked as clinical pharmacist in critical care area and nutrition support. He is He is establish and implement several programs at MOH Hospitals at first time; Clinical Pharmacy Program, Medication Safety Program, Pain Management Program, Anticoagulation Program and Pharmacy Infection Control, including 30 Adult and 20 Pediatrics Clinical Pharmacy Program; he is the founder of Mass Gathering Pharmaceutical Care in Saudi Arabia He became a member of advisory board of the Arab Pharmaceutical Journal in 2010. He became as Pharmacy Board Member of Saudi Commission of Health Care Specialities 2010-2013. He had several research in clinical Pharmacy and Pharmacy practice published in ACCP and ISPOR conferences, He had several presentations in the clinical pharmacy and pharmacy practice at several conference in and outside Saudi Arabia.
Abstract:
National Drug Information Center has started providing services since January 2013; and started answering public andrnprofessional inquires through Ministry of Health Hotline Calling Services (937) since December 2013. Ten on call clinical pharmacist and expert trained pharmacist over 24/7 received calls asking about drug information, through manual documentation system of drug information inquiries. It consisted of type and qualification of caller, type of inquiries, and medications and cost avoidance of expected results of drug related problems sequel of drug information inquires if drugrninformation services did not exist and were not answered using USA model. After 12-months of providing services, therntotal number of answered calls were 976 calls with 264 (27%) answered calls documented; with 300 answered drug inquires.rn60% of inquiries were from the public and 40% were from professionals. The most type of inquiries were about medication identification and dose standardization, followed by drugs in pregnancy, the most medications were asked in both public and professional were antimicrobial. The average costs avoidance per each answered call received was (415.78 USD), and totalrnestimated cost avoidance was (405.801 USD) per year. Hotline calling services of National Drug Information Center is costefficient in Saudi Arabia, it was associated with preventing drug related problems and cost savings per each receiving call. Expanding drug information services with electronic documentation excepted healthcare improvement and better care, better patient outcomes, and reduced costs.